Improving T cell therapy for viral infections after stem cell transplants
Enhancing efficacy of virus-specific T cell therapy following hematopoietic stem cell transplantation by CD52 knockout
['FUNDING_OTHER'] · CHILDREN'S RESEARCH INSTITUTE · NIH-10991125
This study is looking at a new way to make virus-fighting T cells work better for patients who have had a stem cell transplant, by using a special technique to help these cells survive the medications that weaken the immune system, which could lead to better protection against viral infections.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | CHILDREN'S RESEARCH INSTITUTE (nih funded) |
| Locations | 1 site (WASHINGTON, UNITED STATES) |
| Trial ID | NIH-10991125 on ClinicalTrials.gov |
What this research studies
This research investigates how to enhance the effectiveness of virus-specific T cells (VSTs) in treating viral infections in patients who have undergone hematopoietic stem cell transplantation (HSCT). The approach involves using CRISPR technology to knock out the CD52 gene in T cells, which may allow these cells to survive better in the presence of immunosuppressive therapies. By comparing the performance of edited and non-edited T cells, the study aims to determine if this genetic modification improves their ability to fight off multiple viral infections. Patients may benefit from a more effective treatment option that could reduce the risk of severe viral infections post-transplant.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients under 21 years old who are undergoing or have undergone hematopoietic stem cell transplantation and are at risk for viral infections.
Not a fit: Patients who are not undergoing HSCT or who do not have viral infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for viral infections in immunocompromised patients, improving their recovery and overall health outcomes.
How similar studies have performed: Previous research has shown promise in using genetic modifications like CRISPR to enhance T cell therapies, indicating potential success for this approach.
Where this research is happening
WASHINGTON, UNITED STATES
- CHILDREN'S RESEARCH INSTITUTE — WASHINGTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KELLER, MICHAEL DANIEL — CHILDREN'S RESEARCH INSTITUTE
- Study coordinator: KELLER, MICHAEL DANIEL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.